Overview Dividends

(INFU) InfuSystems Holdings - Ratings and Ratios

Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45685K1025

Pumps, Consumables, Rentals, Maintenance, Oncology

Health Care Services
Market Cap in USD: 171m

IPO / Inception: 2007-12-27
Return 12m vs S&P 500: -6.96%

EPS (Earnings per Share)

EPS CAGR: 13.64%
EPS Trend: 64.1%

Last SUE: -1.18
Qual. Beats: 0

Revenue

Rev. CAGR: 8.88%
Rev. Trend: 97.3%

Last SUE: -0.35
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	52.1%
Value at Risk 5%th	79.3%
Relative Tail Risk	-7.45%

Reward TTM
Sharpe Ratio	0.32
Alpha	-9.85
CAGR/Max DD	-0.05

Character TTM
Hurst Exponent	0.643
Beta	1.038
Beta Downside	1.039

Drawdowns 3y
Max DD	58.22%
Mean DD	25.02%
Median DD	20.09%

Description: INFU InfuSystems Holdings November 14, 2025

InfuSystems Holdings, Inc. (NASDAQ: INFU) develops, manufactures, and services infusion pumps and related consumables for oncology and other specialty therapies across the United States and Canada, operating through two primary segments: Patient Services and Device Solutions.

The Patient Services segment focuses on electronic ambulatory infusion pumps and disposable kits used in outpatient chemotherapy, pain management, and other disease-state treatments, while Device Solutions handles the sale and rental of new and pre-owned pole-mounted and ambulatory pumps, along with durable medical equipment, consumables, and full-service biomedical maintenance for hospitals, home-infusion providers, skilled-nursing facilities, and pain centers.

In FY 2023 the company generated approximately $122 million in revenue, with an adjusted EBITDA margin of roughly 12% and a cash balance near $30 million, reflecting a modest but stable cash-flow profile amid a competitive market.

Key sector drivers include the continued shift toward outpatient and home-based oncology care-expected to grow at a CAGR of 7% through 2028-and evolving Medicare reimbursement policies that increasingly favor cost-effective infusion technologies, both of which support demand for INFU’s pump solutions.

For a deeper dive into INFU’s valuation metrics and peer comparison, you might explore the company’s profile on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 8.5

Net Income (5.52m TTM) > 0 and > 6% of Revenue (6% = 8.46m TTM)

FCFTA 0.19 (>2.0%) and ΔFCFTA 16.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 11.95% (prev 12.56%; Δ -0.61pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.25 (>3.0%) and CFO 25.2m > Net Income 5.52m (YES >=105%, WARN >=100%)

Net Debt (23.7m) to EBITDA (24.4m) ratio: 0.97 <= 3.0 (WARN <= 3.5)

Current Ratio 1.90 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (21.2m) change vs 12m ago -2.50% (target <= -2.0% for YES)

Gross Margin 55.35% (prev 50.88%; Δ 4.48pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 138.2% (prev 126.1%; Δ 12.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.23 (EBITDA TTM 24.4m / Interest Expense TTM 1.53m) >= 6 (WARN >= 3)

Altman Z'' -1.65

(A) 0.17 = (Total Current Assets 35.6m - Total Current Liabilities 18.7m) / Total Assets 98.9m

(B) -0.62 = Retained Earnings (Balance) -61.4m / Total Assets 98.9m

(D) -1.40 = Book Value of Equity -60.8m / Total Liabilities 43.4m

Total Rating: -1.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 77.49

1. Piotroski 8.50pt

2. FCF Yield 9.56%

3. FCF Margin 13.22%

4. Debt/Equity 0.45

5. Debt/Ebitda 0.97

6. ROIC - WACC (= 0.30)%

7. RoE 9.92%

8. Rev. Trend 97.29%

9. EPS Trend 64.07%

What is the price of INFU shares?

As of January 08, 2026, the stock is trading at USD 8.91 with a total of 111,017 shares traded.
Over the past week, the price has changed by -0.67%, over one month by +1.83%, over three months by -12.39% and over the past year by +10.27%.

Is INFU a buy, sell or hold?

InfuSystems Holdings has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy INFU.

Strong Buy: 4
Buy: 0
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the INFU price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	14.2	59.4%
Analysts Target Price	14.2	59.4%
ValueRay Target Price	8.9	-0.2%

INFU Fundamental Data Overview January 04, 2026

Market Cap USD = 171.4m (171.4m USD * 1.0 USD.USD)
P/E Trailing = 32.2692
P/E Forward = 25.641
P/S = 1.215
P/B = 3.2885
Beta = 1.711
Revenue TTM = 141.1m USD
EBIT TTM = 11.1m USD
EBITDA TTM = 24.4m USD
Long Term Debt = 20.9m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 24.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.7m USD (from netDebt column, last quarter)
Enterprise Value = 195.1m USD (171.4m + Debt 24.7m - CCE 955.0k)
Interest Coverage Ratio = 7.23 (Ebit TTM 11.1m / Interest Expense TTM 1.53m)
FCF Yield = 9.56% (FCF TTM 18.6m / Enterprise Value 195.1m)
FCF Margin = 13.22% (FCF TTM 18.6m / Revenue TTM 141.1m)
Net Margin = 3.92% (Net Income TTM 5.52m / Revenue TTM 141.1m)
Gross Margin = 55.35% ((Revenue TTM 141.1m - Cost of Revenue TTM 63.0m) / Revenue TTM)
Gross Margin QoQ = 57.06% (prev 55.20%)
Tobins Q-Ratio = 1.97 (Enterprise Value 195.1m / Total Assets 98.9m)
Interest Expense / Debt = 1.87% (Interest Expense 462.0k / Debt 24.7m)
Taxrate = 34.08% (1.17m / 3.43m)
NOPAT = 7.30m (EBIT 11.1m * (1 - 34.08%))
Current Ratio = 1.90 (Total Current Assets 35.6m / Total Current Liabilities 18.7m)
Debt / Equity = 0.45 (Debt 24.7m / totalStockholderEquity, last quarter 55.5m)
Debt / EBITDA = 0.97 (Net Debt 23.7m / EBITDA 24.4m)
Debt / FCF = 1.27 (Net Debt 23.7m / FCF TTM 18.6m)
Total Stockholder Equity = 55.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.59% (Net Income 5.52m / Total Assets 98.9m)
RoE = 9.92% (Net Income TTM 5.52m / Total Stockholder Equity 55.7m)
RoCE = 14.46% (EBIT 11.1m / Capital Employed (Equity 55.7m + L.T.Debt 20.9m))
RoIC = 9.05% (NOPAT 7.30m / Invested Capital 80.6m)
WACC = 8.76% (E(171.4m)/V(196.1m) * Re(9.84%) + D(24.7m)/V(196.1m) * Rd(1.87%) * (1-Tc(0.34)))
Discount Rate = 9.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.37%
[DCF Debug] Terminal Value 62.80% ; FCFE base≈12.3m ; Y1≈8.07m ; Y5≈3.69m
Fair Price DCF = 2.72 (DCF Value 55.3m / Shares Outstanding 20.3m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 64.07 | EPS CAGR: 13.64% | SUE: -1.18 | # QB: 0
Revenue Correlation: 97.29 | Revenue CAGR: 8.88% | SUE: -0.35 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.03 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=0.41 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+42.1% | Growth Revenue=+2.9%

Additional Sources for INFU Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle